Latest Market Entry News

Argosy Minerals reports a 96% lithium recovery from test works at its Rincon Lithium Project and progresses critical energy infrastructure, moving closer to a final investment decision.

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Yari Minerals has validated the high quality of coal at its Rolleston South project, revealing low ash and sulphur levels that promise strong market appeal and underpin a substantial resource base.

Nanoveu Limited reported a dramatic revenue increase driven by its strategic acquisition of Embedded A.I. Systems, while losses widened as it invests heavily in semiconductor commercialisation. The company’s recent $7.5 million capital raise aims to fuel its next growth phase.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Thrive Tribe Technologies reported a $1.8 million half-year loss, driven by a major software impairment and ongoing operational challenges, while raising over $1.5 million in fresh capital to support its evolving business model.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

PointsBet Holdings Limited reports a 4% revenue increase in H1 FY26 following MIXI’s acquisition of a controlling stake, with contrasting performances in Australia and Canada shaping the group’s outlook.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Change Financial has reported a strong first half for FY26 with record revenue growth and its first-ever half-year profit, underpinned by expanding recurring revenues and operational efficiencies.

Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.